NICE said the biggest change from the previous guidance published in 2011 is that the threshold for cardiovascular treatment for high blood pressure has been reduced.
The panel noted that due to existing commissioning arrangement in place for Targeted Therapies for use in Pulmonary Hypertension in Adults, a NICE TA would not add value and the panel subsequently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback